FineMark National Bank & Trust’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

FineMark National Bank & Trust’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,556	Closed	-$23K	–	1124
2016 Q4	$23K	Hold	1,556	–	–	﹤0.01%	801
2016 Q3	$18K	Buy	1,556 +333	+27%	+$3.92K	﹤0.01%	830
2016 Q2	$13K	Buy	1,223 +34	+3%	+$351	﹤0.01%	907
2016 Q1	$11K	Hold	1,189	–	–	﹤0.01%	899
2015 Q4	$18K	Hold	1,189	–	–	﹤0.01%	846
2015 Q3	$20K	Buy	+1,189	New	+$24.3K	﹤0.01%	852

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FineMark National Bank & Trust's MNTA Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2017, closing a stake of 1,556 shares — an estimated $23K sold.

FineMark National Bank & Trust first reported a position in MNTA in Q3 2015 and held it in 6 quarters. The position peaked at $23K in Q4 2016. 162 funds tracked by Wall St. Rank hold MNTA as of Q1 2017.

FineMark National Bank & Trust reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
FineMark National Bank & Trust sold 1,556 Momenta Pharmaceuticals, Inc. shares in Q1 2017, an estimated $23K.
FineMark National Bank & Trust first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2015 and held it in 6 quarters.
FineMark National Bank & Trust's Momenta Pharmaceuticals, Inc. position peaked at $23K in Q4 2016.
162 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.